Modality
ADC
MOA
TROP-2 ADC
Target
SGLT2
Pathway
Ferroptosis
Crohn'sMMGBM
Development Pipeline
Preclinical
Oct 2019
→ Feb 2025
PreclinicalCurrent
NCT07422704
2,336 pts·GBM
2019-10→2025-02·Terminated
2,336 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-02-131.1y agoInterim· GBM
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025
Preclinical
Termina…
Catalysts
Interim
2025-02-13 · 1.1y ago
GBM
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07422704 | Preclinical | GBM | Terminated | 2336 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Tirarapivir | United Therapeutics | Approved | SGLT2 |